News
When it comes to a clinical study to evaluate the therapeutic effect of Shivagutika treatment in patients with HIV, it was ...
The World Health Organization now recommends lenacapavir, a twice-yearly injectable HIV prevention drug, especially for high-risk groups. This endorse ...
A breakthrough HIV drug that only needs to be injected twice a year to offer near-total protection from the virus and ...
SA has accepted an offer of just over R520-million from the Global Fund to Fight Aids, TB and Malaria to buy the twice-a-year ...
2h
AllAfrica on MSNMomentum Builds For Long-Acting HIV Solutions As IAS 2025 Spotlights Scientific Progress, Funding Challenges And Leaders' Calls To ActionNew WHO guidelines endorse long-acting injectable lenacapavir for HIV prevention, Medicines Patent Pool expands licence for long-acting injectable cabotegravir for treatment, and Merck’s once-monthly ...
LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...
22hon MSN
The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention as a tool ...
Zackie Achmat, once at the center of South Africa’s push for lifesaving H.I.V. treatment, has come out of retirement as U.S.
This 2011 electron microscope image made available by the Centers for Disease Control shows HIV virions. On Wednesday, Sept.
3h
TheHealthSite.com on MSNWhat Is Lenacapavir? All About WHO Recommended Biannual HIV Prevention DrugA breakthrough to reduce risk of HIV in adolescents and adults weighing at least 35 kg. WHO releases the new guidelines ...
GENEVA, (CMC)-The World Health Organization (WHO) on Monday advised countries, including those in the Caribbean to ensure ...
As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results